bpc-157 human clinical trials safety regulatory status FDA advisory committee votes to add popular peptide to drug compounding list Repost @peptides with @use.repost ・・・

Yet these therapies should be viewed as adjuncts, not replacements for established treatments

As a targeted intervention that accelerates what your body is already trying to do

obesity trial: cardiometabolic markers, liver fat reduction, lipid profiles Hepatology (2024) Triple agonists in NAFLD/NASH: hepatic steatosis resolution (preclinical and clinical evidence) The Lancet (2023) Supplementary Data Rosenstock et al

Elife , 11 , Prentice-Mott, H

BPC-157 Alone $250/mo 1 per session Targeted gut healing or tendon repair where TB-500 isn't needed

They selectively target pathogenic bacteria while preserving commensal flora